Neutrophils from patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are better at activating the alternative complement system than neutrophils from healthy people, a study has found. This research emphasizes the role of complement in AAV disease development, and suggests the therapeutic potential of its inhibition. The study, titled…
In a new study comparing Rituxan (rituximab) and azathioprine for the treatment of ANCA-associated vasculitis (AAV), rituximab was found to be a cost-effective option, even though it is the more expensive treatment. The study, “Cost-effectiveness of rituximab versus azathioprine for maintenance treatment in antineutrophil…
A piece of an antibody targeting a protein involved in cholesterol transport and metabolism might be an effective treatment for anti-neutrophil cytoplasmic autoantibodies (ANCA) vasculitis, a study suggests. The study, “Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis,” was published in …
Lower doses of Rituxan (rituximab) appear to be as safe and effective as the standard Rituxan regimen for inducing remission in ANCA-associated vasculitis (AAV) patients, a retrospective Japanese study suggests. The study, “Low-dose rituximab as induction therapy for ANCA-associated vasculitis,” was published in Clinical Rheumatology.
Get regular updates to your inbox.